{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:54:33Z","timestamp":1765886073316,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"am","delay-in-days":408,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jacl.2017.09.006","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T08:02:02Z","timestamp":1507881722000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9926-2179","authenticated-orcid":false,"given":"Terry A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.jacl.2017.09.006_bib1","first-page":"3","article-title":"CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors\u2013United States, 2005-2013","volume":"63","author":"Johnson","year":"2014","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.jacl.2017.09.006_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"25 suppl 2","key":"10.1016\/j.jacl.2017.09.006_bib3","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.09.006_bib4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacl.2017.09.006_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jacl.2017.09.006_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2017.09.006_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2017.09.006_bib8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"9326","key":"10.1016\/j.jacl.2017.09.006_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.09.006_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.09.006_bib11","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.09.006_bib12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2017.09.006_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey on 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2017.09.006_bib14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.09.006_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jacl.2013.10.006","article-title":"Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study","volume":"8","author":"Ito","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2017.09.006_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2017.09.006_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacl.2016.05.003","article-title":"Metabolic syndrome is associated with muscle symptoms among statin users","volume":"10","author":"Brinton","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.09.006_bib18","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.09.006_bib19","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.09.006_bib20","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.09.006_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.09.006_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jama.2015.1335","article-title":"Statin intolerance: reconciling clinical trials and clinical experience","volume":"313","author":"Newman","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.09.006_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/2047487315602861","article-title":"Statin tolerability: in defence of placebo controlled trials","volume":"23","author":"Tobert","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2017.09.006_bib24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2017.09.006_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs. ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"15","key":"10.1016\/j.jacl.2017.09.006_bib26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"7 Suppl","key":"10.1016\/j.jacl.2017.09.006_bib27","first-page":"S35","article-title":"Diagnosis, prevention and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"issue":"17","key":"10.1016\/j.jacl.2017.09.006_bib28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2017.09.006_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"issue":"23","key":"10.1016\/j.jacl.2017.09.006_bib30","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.09.006_bib31","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2017.09.006_bib32","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.09.006_bib33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2017.09.006_bib34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2017.09.006_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"6 Suppl","key":"10.1016\/j.jacl.2017.09.006_bib36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2017.09.006_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.09.006_bib38","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.09.006_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2017.09.006_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.09.006_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40271-016-0211-y","article-title":"Development and content validity of the Statin Experience Assessment Questionnaire (SEAQ)\u00a9","volume":"10","author":"Jacobson","year":"2017","journal-title":"Patient"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:27Z","timestamp":1761831207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417304592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1933287417304592"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.09.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}